/
REGN
$738.34+$42.92 (+6.17%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
3
institutions
Market cap
$76.0B
103M shares
52-week range
$541.00 – $821.11
70% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change+$161.21
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
www.regeneron.com- Employees
- 15,410
- IPO / List date
- Apr 2, 1991
- HQ
- TARRYTOWN, NY
Held by traders on TradeandTell
No one on the platform currently holds REGN.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Scion Asset ManagementCALLas of 2025-06-30 | 200,000 | $105.0M |
| Renaissance Technologiesas of 2026-03-31 | 66,802 | $51.6M |
Dividend history
TTM yield · 0.50% ($3.70/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-08-18 | $0.9400 | 2026-08-31 |
| 2026-05-20 | $0.9400 | 2026-06-04 |
| 2026-02-20 | $0.9400 | 2026-03-05 |
| 2025-11-20 | $0.8800 | 2025-12-05 |
| 2025-08-18 | $0.8800 | 2025-09-03 |
| 2025-05-20 | $0.8800 | 2025-06-06 |
| 2025-02-20 | $0.8800 | 2025-03-20 |
Recent trades on TradeandTell
No one on the platform has traded REGN yet.
